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Kadir Oznam d, Akin Ugras d, Mahir Mahiroğullari e
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A B S T R A C T
Aim: We aimed to reveal whether there are prospective suggestions for effective and standard platelet-
rich plasma applications.
Methods: We searched for clinical trials and traced all the references of incorporated documents.
Results: In literature, there was no study indicating which disease is treated by which mechanism of
action, how much dose and content are prepared and applied, when the treatment is applied and how
many cures are applied.
Conclusion: Guides introducing which concentrations of PRP are used for which diseases are to be
prepared immediately by a committee which is comprised of primarily orthopedists, clinical
pharmacologists and toxicologists.
 2016 Prof. PK Surendran Memorial Education Foundation. Published by Elsevier, a division of Reed
Elsevier India, Pvt. Ltd. All rights reserved.
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Health-related quality of life is decreasing year by year in the
world due to muscle and musculoskeletal injuries.1 As there have
not been promising results in the present studies regarding
treatment of these injuries, clinical and social problems come up.
Scientists turn towards repair of damaged tissues using biological
methods in their studies.2
As the number of studies regarding the growth factors in wound
healing and their interaction increases, it paves the way for
personal and cell-based biological treatments, which can be
applied as self-executing and combined. While treating damaged
tissues, treatments that can provide rapid tissue repair and
functional healing, and treatment modalities that are biological-
oriented are targeted. In this respect, PRP constitutes an important
step.3* Corresponding author. Tel.: +90 53 2701 2858; fax: +90 28 2262 5355.
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guraybatmaz@hotmail.com (A.G. Batmaz), olcayguler77@gmail.com (O. Guler),
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http://dx.doi.org/10.1016/j.jor.2016.06.027
0972-978X/ 2016 Prof. PK Surendran Memorial Education Foundation. Published by PRP has gained popularity, which allows non-pharmaceutic and
biologic repair-oriented recovery process by releasing local growth
factors in the environment. Besides, it has functions of homeostasis
and coagulation. It involves PLT, which abundantly contains
cytokine and growth factors that are important in tissue repair and
bone mineralization.4 Furthermore, it contains lots of growth
factors – in protein and peptide structure – which play key roles in
synthesis of tissue matrix.5
As a result, in literature, PRP is reported to affect not only
resorption of necrotic tissues but also macrophages which
accelerate tissue healing, mesenchymal stem cells and osteoblasts.
It is also reported to cause release of bioactive proteins.6 For this
very reason, it is applied in all fields of medicine including
orthopaedic surgery in tissue damage treatments.7,8
PRP’s use has been increasing in many cases such as primarily
osteoarthritis,9 proximal hamstring,10 Achilles,11 patellar tendi-
nopathies,12 talar osteochondral lesions,13 rotator cuff damage
repair,14 lateral epicondylitis treatment,15 relieving pains follow-
ing arthroplasty8 and contributing to bone healing of tibia in
distraction osteogenesis.8
However, as there are contradictory results reported in some
cases in literature where PRP was applied, there are some
questions regarding the efficiency of PRP treatment.16–18 SomeElsevier, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.
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superior in clinical treatment.19 There was no well-proven study
in which PLT and leucocyte (WBC) rates were separately discussed
in PLT concentrations in PRP content. There was not enough
evidence regarding how much WBS is responsible from curative or
negative effect in clinics.20,21
Recently, the use of PRP has gained popularity and has become a
treatment option all by itself.22 There are some questions to be
answered such as to whom, when, how and by which mechanism it
is to be applied. It is important that a standardization be processed
in consequence of basic and clinical studies as using different
commercial kits might result in different results, which leads some
issues concerning the evaluation of clinic studies.
The purpose of the present study is to determine the different
applications of PRP in clinics after reviewing the literature and set
forth whether there are suggestions for efficient and standard PRP
application.
2. Materials and methods
2.1. Search strategy
The databases of the US National Library of Medicine National
Institutes of Health, Embase, OVID and the Cochrane Library, as
well as the references within the retrieved articles were searched
to find all relevant orthopaedic injury and PRP clinical trial studies
from 1954 to June 4, 2016, without any language restrictions. The
following keywords were used in the search: ‘‘platelet-rich
plasma’’, ‘‘PRP’’, ‘‘OA’’, ‘‘proximal hamstring’’, ‘‘achilles tendino-
pathy’’, ‘‘patellar tendinopathy’’, ‘‘talar osteochondral lesions’’,
‘‘rotator cuff’’, ‘‘lateral epicondylitis’’ and/or PRP.
The percentage distribution of articles by year was recorded,
and the evidence level was determined according to Lijmer
et al.23,24 Bibliographies thought to be missed during the database
research were examined again. Unpublished grey literature,
including articles, comments, letters, editorials, protocols, guides,
meta-analyses and collections were not included. The most highlyFig. 1. The follow chart of licited articles were defined and re-examined in order to avoid
double entries.
2.2. Eligibility criteria
Double-blind placebo-controlled randomized clinical trials or
researches of level I were included to our study. All studies not
containing the above information were excluded. The study
inclusion process is summarized in Fig. 1.
2.3. Data collection and evaluation
The authors selected the included studies independently and, in
order to minimize selection bias, the studies were revised by all
authors. In the event of conflicting results, the final decision was
taken by authors, who have greater experience regarding PRP
preparations design. Finally, the senior authors were consulted and
the topics were revised, if necessary.
2.4. Statistical analysis
It was found that the obtained data are not based upon the fact
that they were collected from the sources that had probability
distribution function. Therefore, non-pragmatic statistical meth-
ods were used. Nonetheless, given the lack of common findings,
statistical analyses could not be performed and complementary
statistical methods were applied instead. Microsoft Office Excel
(2010) was used and the results were shown as mean  standard
deviation or frequency (%).
3. Results
A total of 13,248 studies were found to have potential for
inclusion. The number of articles published per year is shown in
Fig. 2. Following revision of the full text, 10 articles were finally
included (Table 1), all of which were comparative, randomized
controlled clinical trials.8–14,25–27teratures identification.
Fig. 2. The frequency of the studies of PRP by years.
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PRP were made. When the literature is reviewed, no study has
been found purporting the effective dose to be used in
treatments. Besides, we observed whether PRP content was
tested by pharmaco-molecular analyses. In literature, there was
no study indicating which disease is treated by which
mechanism of action, how much dose and content are prepared
and applied, when the treatment is applied and how many cures
are applied.
4. Discussion
Upon reviewing the literature, we could not find a standardized
production monograph as different companies use different
commercial kits. In addition, there was no precise information
regarding in which circumstances PRP was obtained and maxi-
mum or minimum revolutions per minute/centrifugal force/
capacity of the centrifuges which were used. Consensus that
was reached in these studies on obtaining PRP was the number,
speed and time of centrifuge. Last but not the least, another thing
that was agreed was the thickness of needle to be used during
blood intake from donors and after obtaining PRP. The reason for
this was as diameter of needles decreases, growth factors in PLT
might affect the release time. It was reported that PLT might lead to
premature activation, so 21-gauge injector nozzles should be used
during autologous blood intake and PRP application.28,29
Apart from these there was no well-proven study in which
activation of PRP was mentioned and whether it was activated or
not. There were some preclinical30 and clinical31,32 studies, but
there was no consensus on a protocol.
In literature, it was reported that early immature activation and
growth factors release during the preparation of PRP pose other
problems. It was emphasized that when a double spin centrifuge
method was used, PLT concentration rate was 10% of the total
blood taken from cases. However, more blood intake was needed
when a single spin centrifuge method was used.33 Furthermore, it
was found that PRPs obtained from autologous plasma were
directly used without considering their content, from which
disease and at what dose they were obtained.7–22,34However, as it is known, growth factors in PRP are various.34 It
is also known that transforming growth factor beta-1 induces
chondrogenic activity2 and fibroblastic growth factor; bone
morphogenetic protein-2, -4, -6 induces osteoblastic stimulation
and osteogenesis,2,35 bone morphogenetic protein-12 induces
tenogenic activity.36 Nonetheless, without knowing the concen-
tration of growth factors in PRP content and compound, they are
applied. Although bone morphogenetic proteins are highly
concentrated, they can be applied in cartilage damages. Similarly,
though transformer growth factor in PRP has high incidence, it can
be used in bone healing.
Recent well-proved studies have reported that half-life of
growth factors is maximum 2 min.37–40 It was emphasized that
when growth factors – with protein and peptide structure – in PRP
obtained from human were applied after that period, bioactivity
decreased and even vanished.37–40
When the studies in which PRP was obtained from autologous
blood in clinics were considered, it was found that it was prepared
from 10 to 20 min.7–21 Nevertheless, it takes time to apply it to
cases, which makes its bioactive and effective treatment results
controversy.
In a study, treatments of PRP and hyaluronic acid (HA) were
compared in cases with cartilage defect and osteochondropathy
(n = 109) with the purpose of evaluating the effectiveness of PRP,
which contains high incidence of growth factor. 55 cases were
applied HA whereas 54 were applied PRP and followed for
12 months. Clinical evaluations were made by means of
International Knee Documentation Committee (IKDC), EuroQol
(EQ) – Visual Analogue Scale (VAS), Tegner Lysholm Knee Scoring
Scale (TLKS), and Knee injury and Osteoarthritis Outcome Score
(KOOS), circumference measurement of knee and goniometric
measurement of the knee range. As a result, it was observed that
cases in both groups had recovery, but cases with PRP applied
early-stage defects had better recovery. On the other hand, it was
emphasized that the recovery in midlife early-stage osteoarthritis
was not superior to the HA applied cases contrary to the
literature.25
Dragoo et al. injected PRP to cases (n = 23) with patellar
tendinopathy by means of ultrasonography. Whereas 10 cases
Table 1
Characteristics of the included studies.
Are WBC/PLT values
in PRP content formed
following dose
response curve?
Is PRP content
tested at a
molecular level?
Are there any
explanations
about which
diseases are
treated by which
mechanism of action?
Are there any
explanations about
what dosage is
prepared in what
content, when and
how many cures
are used?
Filardo G et al.25 (2012) Platelet-rich plasma vs
hyaluronic acid to treat knee
degenerative pathology: study
design and preliminary results of
a randomized controlled trial.
– – – –
Dragoo JL et al.12 (2014) Platelet-rich plasma as a
treatment for patellar
tendinopathy: a double-blind,
randomized controlled trial.
– – – –
Malavolta EA et al.14 (2014) Platelet-rich plasma in rotator
cuff repair: a prospective
randomized study.
– – – –
Filardo G et al.11 (2014) Platelet-rich plasma injections
for the treatment of refractory
Achilles tendinopathy: results at
4 years.
– – – –
Duif C et al.8 (2015) Does intraoperative application
of leukocyte-poor platelet-rich
plasma during arthroscopy for
knee degeneration affect
postoperative pain, function and
quality of life? A 12-month
randomized controlled
double-blind trial.
– – – –
Gobbi A et al.9 (2015) The effects of repeated
intra-articular PRP injections on
clinical outcomes of early
osteoarthritis of the knee.
– – – –
Davenport KL et al.10 (2015) Ultrasound-guided
intratendinous injections with
platelet-rich plasma or
autologous whole blood for
treatment of proximal hamstring
tendinopathy: a double-blind
randomized controlled trial.
– – – –
Filardo G et al.26 (2015) Platelet-rich plasma
intra-articular knee injections
show no superiority vs
viscosupplementation: a
randomized controlled trial.
– – – –
Görmeli G et al.13 (2015) Clinical effects of platelet-rich
plasma and hyaluronic acid as an
additional therapy for talar
osteochondral lesions treated
with microfracture surgery: a
prospective randomized clinical
trial
– – – –
Montalvan B et al.27 (2016) Inefficacy of ultrasound-guided
local injections of autologous
conditioned plasma for
recentepicondylitis: results of a
double-blind placebo-controlled
randomized clinical trial with
one-year follow-up.
– – – –
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6th, 9th and 12th weeks, they carried out clinical evaluation using
Victorian Institute of Sports Assessment (VISA) scoring. In addition,
during 12th and 26th weeks, they obtained secondary data using
VAS, TLKS and Short Form (SF-12) questionnaire. After 12 weeks,
they reported that they observed an increase by 5.2 in dry needling
application in VISA scoring. Nevertheless, they reported that the
increase was by 25.4 in PRP applied group. Following 26th week,
they observed that the increase in dry needling group was by
33.2 whereas it was by 28.9 in PRP group. On the other hand, they
emphasized that although there was not an increase in PRP groupin the 12th week, there was not a significant difference between
the groups in the 26th week.12
Dohan Ehrenfest et al., in their manuscript, informed that PLT
concentrations – through topical and infiltrating routes – gained
popularity primarily in sports medicine and orthopaedic surgery.
Nonetheless, although they presented treatment perspective, they
reported that the studies in literature were confusing. They
classified PRP products into 4 main groups in order to benefit from
them in advanced stage researches; pure platelet-rich plasma
(P-PRP), such as the PRGF-Endoret technique; leukocyte- and
platelet-rich plasma (LPRP), such as Biomet GPS system; pure
I. Yilmaz et al. / Journal of Orthopaedics 13 (2016) 316–321320platelet-rich fibrin (P-PRF), such as Fibrinet; leukocyte- and
platelet-rich fibrin (L-PRF), such as Intra-Spin L-PRF. They under-
lined the fact that this classification should be improved and
reported that there are discussions on cell content, storage
conditions and/or activation.20
Malavolta et al. studied effectiveness of PRP injections used in
rotator cuff repair. They included 54 cases and divided them into
two groups. Complete supraspinatus tears with retraction of less
than 3 cm were subjected to arthroscopic single-row repair; at the
end of the surgical procedure, liquid PRP prepared by apheresis
was given to the patients in the PRP group with autologous
thrombin. In clinical evaluations, University of California at Los
Angeles (UCLA) and Constant scales, VAS and magnetic resonance
imaging were used during the 3rd, 6th, 12th and 24th months after
the surgery. They indicated that when they compared the cases in
two groups in terms of 24-month follow-up, UCLA score increased
from 13.63 in the PRP group while it increased from 13.93 to
32.44. In addition, they stated that Constant score increased from
47.37 to 85.12 in the control group whereas it increased from
46.96 to 84.78. As for VAS score, it decreased from 7 to 1.15 in the
control group whereas it decreased from 6.67 to 0.96. They also
reported that 1 case had recurrent complete tear and 4 cases had
partial tear in the control group, whereas 2 cases had partial tear in
the PRP group.14
In another study, PRP application results, which include high
leucocyte were researched in cases with chronic achilles tendino-
pathy (n = 27), which resulted from decreasing physical perfor-
mance. In this study, cases were applied PRP 3 times every other
2 weeks consequently. Blazina, VISA, EQ-VAS and TLKS were used
to evaluate cases before and during the 2nd, 6th and 54-month
follow-up. As a result, they concluded that the results of PRP
injection were promising and stabilized when they had been
evaluated in the mid phase.11
Duif et al. used leukocyte-poor platelet-rich plasma (LP-PRP) to
evaluate effects that occurred during the arthroscopic treatment of
knee lesions, which have detrimental effects concerning pain,
function and quality of life. To this end, they applied randomized
and double blind study in cases with knee arthroscopy (n = 58). The
control group was comprised of 34 cases whereas the workgroup
was comprised of 24 cases. They injected LP-PRP intra-articular to
cases in workgroup during arthroscopy process. The function of
knee was evaluated during the first application, 6th and 12th weeks
in terms of quality of life. At the end of 12th month, they reported
that 91% of the cases in the group where LP-PRP was applied during
the 6th month had less pain, yet there was no significant difference
across the groups at end of the 12th month in terms of quality of life.
They concluded that during 6–12 months post-op period, intra-
operative LP-PRP applied group was superior to other groups as far
as pain relief and functionality of knee was concerned.8
Gobbi et al. investigated to find out whether intra-articular
applied PRP at cyclic dose to cases with early stage osteoarthritis
would affect treatment results, so they followed 113 knees of
93 cases for approximately 2 years. They applied PRP at the end of
the first year. The cases before the injection and during the 12th,
18th and 24th months after the injection were assessed by KOOS,
VAS, Tegner and Marx activity scales systems. They informed that
all scored show that there was a significant improvement when
compared to the pre-treatment. On the other hand, they
emphasized that in the group where PRP was applied during the
18th month as the second cycle, there was a significant
improvement in other parameters except for KOOS and Tegner
scores. They concluded that a regression occurred at the end of the
2nd year; still, it was not statistically significant.9
Görmeli et al. compared HA and PRP applicants in osteochon-
dral ankle injuries, which affect talus dome and lead to athletic
disability, so they included arthroscopic micro-fracture cases(n = 40) in their study. They injected PRP to 13 cases, HA to 14 cases
and the rest of the cases were injected saline. All cases were
evaluated by American Orthopedics Foot and Ankle Society
(AOFAS) functional scale and VAS scores before and after
15.3 months (in average) the application. They underlined that
all cases showed an increase in AOFAS scores, and a decrease in VAS
scores. They also maintained that AOFAS score was significantly
higher in PRP than saline and HA groups. They stated that AOFAS
score was higher in HA group than saline group. As for VAS scoring,
they maintained that there was a significant decrease in PRP group
than saline and HA groups. They concluded that PRP should be used
primarily in talar osteochondral damages as the results of PRP
group was better.13
Davenport et al. compared PRP and total blood applications in
cases with chronic hamstring tendinopathy. Before the application
and during the 2nd, 6th, 12th week and the 6th month, they
measured pain and function outcomes via the Modified Harris Hip
Score (MHHS), Hip Outcome Scores for activities of daily living
(ADL) and sport-specific function, and International Hip Outcome
Tool 33 (IHOT-33) scoring. They reported that before 12th week,
total blood results were better than PRP applications where PRP
application results were better at the end of the 6th week. The
cases in PRP group showed significant increase in ADL and IHOT-33
scoring during 6th month when compared to pre-injection, yet it
was not the case in total blood applications.10
In another manuscript, PRP and HA injected groups were
compared in cases with osteoarthritis (n = 192). The cases were
injected PRP and HA for the purpose of delay of surgery. They
included cases who had unilateral knee pain for at least four months
and with Kellgren-Lawrence score of 0–3 at radiographs or MRI
evidence of degenerative chondropathy. The cases were applied PRP
and HA injections every other week and 3 times in total. They used
IKDC subjective score, KOOS, EQ-VAS and TLKS while evaluating the
cases. Following PRP application, they reported that swelling and
pain occurred in the injection area. They reported that IKDC score
increased from 52 to 66 in PRP group whereas it increased from
49 to 64 in HA group. They emphasized that PRP and HA groups did
not gain an advantage over each other.26
Montalvan et al. studied intratendinous effect of PRP in cases
who had epicondylitis for less than 3 months. They included cases
who had PRP and saline injections which was accompanied by
ultrasonography four weeks apart. Cases were evaluated by blind
study criteria. Following the isometric spasm of extensor carpi
radialis and extensor digitorum communis muscles, the cases were
assessed by VAS and Roles Mandsley scoring during 1st, 3rd, 6th
and 12th months. As a result, two groups had promising results;
still, there was no difference between two groups after 6 months.27
Given the low number of studies and the conflicting results
between these, performing a meta-analysis of the results and
deciding which of these results should be disregarded or included
is a difficult task. Nevertheless, it is important for such data to be
compiled and compared.24
The studies included in the present review did not provide
common data and therefore homogeneity or heterogeneity tests
could not be performed. As a result of this study, it can be concluded
that the hypothesis that there is only one real underlying effect that
to be predicted cannot be justified statistically. For this reason, the
graph drawing of the data regarding sample quantity or variation
reciprocal could not be realized. In the present study, all the articles
were retrospectively designed and most had small sample sizes
subject to systematic and random bias.
5. Conclusion
There is a need to establish worldwide multicentre study set-ups
in which volunteers from all races take part. These set-ups include
I. Yilmaz et al. / Journal of Orthopaedics 13 (2016) 316–321 321dose response curves of WBC ratio in PRP content. Afterwards, they
should be tested as pre-clinic and clinic at molecular level. It is
important to clarify which treatment is received, which mechanism
of action is used and which disease is treated. Some questions
concerning application of treatment on which cases, amount of
doses, duration and number of cures are to be answered. Through
the results of these studies, guides introducing which concentra-
tions of PRP are used for which diseases are to be prepared
immediately by a committee which is comprised of primarily
orthopaedists, clinical pharmacologists and toxicologists.
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